{"filing":{"accession_number":"0001213900-26-060879","cik":"0001859807","ticker":"NVACW","company_name":"Profusa, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"ea0292151-8k_profusa.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1859807/000121390026060879/ea0292151-8k_profusa.htm"},"events":[{"id":9059,"run_id":7954,"accession_number":"0001213900-26-060879","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"This disclosure concerns a First Amendment to an Asset Purchase Agreement dated May 22, 2026, modifying the Company's acquisition of substantially all know-how assets relating to Bio Insights LLC's PanOmics Assay platform for $30 million in Series A Convertible Preferred Stock. While the Amendment primarily deletes the Management Shares provision (12% equity grant to executives), it is filed under Item 1.01 and relates to a material acquisition transaction previously disclosed on April 27, 2026. The $30 million purchase price and strategic nature of the PanOmics Assay assets (NGS multi-omics platform for drug discovery and precision medicine) constitute a material acquisition activity.","company_name":"Profusa, Inc.","ticker":"NVACW","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1546,"accession_number":"0001213900-26-060879","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This disclosure concerns a First Amendment to an Asset Purchase Agreement dated May 22, 2026, modifying the Company's acquisition of substantially all know-how assets relating to Bio Insights LLC's PanOmics Assay platform for $30 million in Series A Convertible Preferred Stock. While the Amendment primarily deletes the Management Shares provision (12% equity grant to executives), it is filed under Item 1.01 and relates to a material acquisition transaction previously disclosed on April 27, 2026. The $30 million purchase price and strategic nature of the PanOmics Assay assets (NGS multi-omics platform for drug discovery and precision medicine) constitute a material acquisition activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:13:47.187199+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1546,"accession_number":"0001213900-26-060879","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This disclosure concerns a First Amendment to an Asset Purchase Agreement dated May 22, 2026, modifying the Company's acquisition of substantially all know-how assets relating to Bio Insights LLC's PanOmics Assay platform for $30 million in Series A Convertible Preferred Stock. While the Amendment primarily deletes the Management Shares provision (12% equity grant to executives), it is filed under Item 1.01 and relates to a material acquisition transaction previously disclosed on April 27, 2026. The $30 million purchase price and strategic nature of the PanOmics Assay assets (NGS multi-omics platform for drug discovery and precision medicine) constitute a material acquisition activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:13:47.187199+00:00","company_name":"Profusa, Inc.","ticker":"NVACW","filing_date":"2026-05-26"}]}